Arcutis Biotherapeutics Inc (ARQT)
Arcutis Biotherapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases. Its lead product is ZORYVE, a topical roflumilast cream approved for plaque psoriasis and atopic dermatitis. The company is also advancing ZORYVE foam for seborrheic dermatitis, as well as scalp and body psoriasis, alongside ARQ-234, a fusion protein designed as a selective checkpoint agonist of the CD200 receptor. Founded in 2016, the company changed its name from Arcutis, Inc. in October 2019 and is headquartered in Westlake Village, California. Arcutis Biotherapeutics common stock trades on the NASDAQ under the symbol ARQT.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ARQT
|
$29.28
|
4.9% Upside
|
Fair
|
$34.63
|
24.1% Upside
|
Undervalued
|
Great
|
—
|
—
|
—
|
0.0%
|
August 5, 2026
|
-1,472.5x
|
18.4x
|
8.4x
|
3.444 B
|
3.389 B
|
3.2%
|
73.9%
|
5.7
|
—
|
-1,132.8%
|
